| 2026-08-31 | Press release | New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable eff |
| 2026-08-31 | Press release | Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases |
| 2026-08-28 | Press release | La FDA aprueba Mounjaro (tirzepatida) de Lilly para reducir el riesgo cardiovascular en adultos con diabetes tipo 2 |
| 2026-08-28 | Press release | FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes |
| 2026-08-26 | Press release | Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study |
| 2026-08-12 | Press release | Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market |
| 2026-08-05 | Press release | Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipe |
| 2026-08-05 | Press release | Press Release |
| 2026-08-03 | Press release | Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12 |
| 2026-07-23 | Press release | Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improve |
| 2026-07-22 | Press release | Lilly confirms date and conference call for second-quarter 2026 financial results announcement |
| 2026-07-16 | Press release | Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions |
| 2026-07-09 | Press release | Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 bl |
| 2026-06-26 | Press release | Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocy |
| 2026-06-26 | Press release | Lilly launches “The Memory Radio Station” across Europe, inviting the public to visually reconstruct fading memories thr |
| 2026-06-25 | Press release | What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight |
| 2026-06-24 | Press release | Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders |
| 2026-06-06 | Presentation | Lilly Investor Event at American Diabetes Association's (ADA) Presentation |
| 2026-04-29 | Press release | Press Release |
| 2026-04-07 | Quarterly report | Estimated Acquired IPR&D And Development Milestone Charges for Q1 2026 |
| 2026-02-04 | Press release | Q4 2025 Lilly Press Release |
| 2025-10-30 | Press release | Press Release |
| 2025-08-07 | Press release | Q2 2025 Lilly Press Release |
| 2025-05-09 | Regulatory report | 0000059478-25-000142.pdf |
| 2025-05-01 | Press release | Q1 2025 Lilly Press Release |
| 2025-05-01 | Presentation | Q1 2025 Lilly Presentation |
| 2025-02-10 | Prospectus | 0001193125-25-023658.pdf |
| 2025-02-06 | Press release | Q4 2024 Lilly Press Release.pdf |
| 2024-10-30 | Press release | Q3 2024 Lilly Press Release.pdf |
| 2024-08-12 | Prospectus | 0001193125-24-198946.pdf |
| 2024-08-08 | Earnings deck | Earnings Presentation |
| 2024-08-08 | Press release | Q2 2024 Lilly Press Release.pdf |
| 2024-05-03 | Regulatory report | 0000059478-24-000124.pdf |
| 2024-04-30 | Earnings deck | Earnings Presentation |
| 2024-04-30 | Press release | Q1 2024 Lilly Press Release.pdf |
| 2024-04-11 | Proxy statement | 0001214659-24-006578.pdf |
| 2024-02-07 | Prospectus | 0001193125-24-026801.pdf |
| 2024-02-06 | Earnings deck | Earnings Presentation |
| 2024-02-06 | Press release | Q4 2023 Lilly Press Release.pdf |
| 2023-11-02 | Earnings deck | Earnings Presentation |